Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in recurrent EGFR+ PTEN wild-type glioblastoma
NCT00387894Phase 2Terminated
- Sponsor
- Michael Prados
- Start
- Jan 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in glioblastoma multiforme (GBM) and Gliosarcoma (GS), sponsored by Michael Prados. Primary endpoint: Objective Response Rate. Started Jan 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00387894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387894.